Compare Ascendis Pharma A/S (ASND) vs Marathon Digital Holdings Inc (MARA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Marathon Digital Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Marathon Digital Holdings Inc trades at $12.5 (market cap $4.80B). The key difference: Ascendis Pharma A/S is far larger — about 3.7× Marathon Digital Holdings Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ASND | MARA | |
|---|---|---|
Market Cap | $17.74B | $4.80B |
Sector | Health | Technology |
52-Week High | $277.18 | $22.84 |
52-Week Low | $163.32 | $6.73 |
Enterprise Value | $18.11B | $6.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MARA Holdings trades at $12.60, down 4.69% on the day, amid mixed signals. The stock shows a bullish technical trend with strong support at $12, while fundamentals reveal deep losses with a net income margin of -234.83% in 2026. Recent news highlights a strategic pivot to AI infrastructure, including a Texas land acquisition adding 2 GW power capacity, driving investor optimism despite earnings misses.
Outlook hinges on successful execution of AI data center expansion, offering growth potential but carrying high execution risk. Analysts maintain a $17.88 price target (50% buy rating), yet persistent cash burn and competitive pressures pose significant downside risks. Stock appears speculative, balancing transformative opportunities against substantial financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →
